PS899877 | 1140489-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: PS899877
• 英文别名: (R)-2-(4-(4-chlorobenzyl)-5-methyl-4H-1,2,4-triazol-3-yl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-1-carboxamide；(2R)-2-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-N-[4-(trifluoromethyl)phenyl]pyrrolidine-1-carboxamide
• CAS: 1140489-56-0
• 化学式: C₂₂H₂₁ClF₃N₅O
• 分子量: 463.89
• InChiKey: WPOWUOQNLIGLKJ-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  63
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-4-(4-chlorobenzyl)-3-methyl-5-(pyrrolidin-2-yl)-4H-1,2,4-trazole hydrochloride 、 4-三氟甲基苯基异氰酸酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以53%的产率得到PS899877
  参考文献：
  名称：

  Novel pyrrolidine heterocycles as CCR1 antagonists

  摘要：

  A novel series of pyrrolidine heterocycles was prepared and found to show potent inhibitory activity of CCR1 binding and CCL3 mediated chemotaxis of a CCR1-expressing cell line. A potent, optimized triazole lead from this series was found to have acceptable pharmacokinetics and microsomal stability in rat and is suitable for further optimization and development. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.082

文献信息

• ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION
  申请人：Paradkar Vidyadhar M.

  公开号：US20090093472A1

  公开（公告）日：2009-04-09

  Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

  公式为的化合物已被披露。这些化合物是CCR1拮抗剂，可用于治疗和预防炎症性和自身免疫性疾病。其他实施例也已披露。
• Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation
  申请人：Pharmacopeia, LLC

  公开号：US08288371B2

  公开（公告）日：2012-10-16

  Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

  本发明揭示了一种公式为的化合物。这些化合物是CCR1拮抗剂，可用于治疗和预防炎症和自身免疫性疾病。本发明还揭示了其他实施方案。
• USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Merritt James

  公开号：US20170112831A1

  公开（公告）日：2017-04-27

  The present disclosure relates to Chemotactic Cytokine Receptor 1 (CCR1) antagonists and their use in the treatment of tumors of the central nervous system. More specifically, to the treatment of Astrocytic tumors.
• US8288371B2
  申请人：——

  公开号：US8288371B2

  公开（公告）日：2012-10-16
• [EN] USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM<br/>[FR] UTILISATION D'ANTAGONISTES DE CCR1 EN TANT QUE TRAITEMENT DE TUMEURS DU SYSTÈME NERVEUX CENTRAL
  申请人：MERRITT JAMES

  公开号：WO2017070431A1

  公开（公告）日：2017-04-27

  The present disclosure relates to Chemotactic Cytokine Receptor 1 (CCRl) antagonists and their use in the treatment of tumors of the central nervous system. More specifically, to the treatment of Astrocytic tumors.